Your Cholesterol Isn't the Whole Story: The Mutated Blood Cells Scientists Are Linking to Heart Disease

A dramatic claim circulating online suggests that mutated blood stem cells explain up to 40% of fatal heart attacks and strokes in people with normal cholesterol, that statins cannot address the danger, and that anti-inflammatory treatment can sharply reduce the risk.

There is a real scientific discovery behind this story. But some of the conclusions go further than the evidence allows.

Researchers have found that certain age-related mutations in blood-forming stem cells are associated with an increased risk of cardiovascular disease. The condition is called clonal hematopoiesis of indeterminate potential, or CHIP.

A 2026 scientific statement from the American Heart Association describes clonal hematopoiesis as an emerging cardiovascular risk factor. Studies suggest that some mutated blood cells can encourage inflammation that contributes to artery disease.

That is important. It does not prove that CHIP explains 40% of fatal heart attacks, that statins are ineffective in people with CHIP, or that a particular anti-inflammatory treatment is proven to protect them.

Let's separate the discovery from the hype.

What is CHIP?

Your bone marrow continually produces the blood cells your body needs. Over time, some of the stem cells that produce those cells acquire changes in their DNA.

These mutations are acquired during life, not inherited from your parents.

Most acquired mutations do not create a major problem. But occasionally, a mutated stem cell gains a competitive advantage and produces more descendants than neighboring cells. A population of blood cells carrying the same mutation gradually expands.

This is called clonal hematopoiesis. When the mutation meets specific criteria and there is no diagnosed blood cancer or unexplained low blood-cell count, it may be classified as CHIP.

Genes commonly involved include DNMT3A and TET2. These genes help regulate how cells use their genetic instructions.

CHIP becomes more common with age. Its prevalence also depends on the size of the mutated cell population and how sensitive the DNA-sequencing test is. Studies using more sensitive methods can detect smaller populations of mutated cells than older tests.

CHIP is not the same as leukemia. Most people with CHIP do not develop a blood cancer, although their risk is higher than that of people without these mutations.

How could mutated blood cells affect your heart?

The connection involves inflammation.

Atherosclerosis—the buildup of plaque inside arteries—is not simply cholesterol accumulating in the artery wall. It also involves the immune system.

Certain white blood cells enter artery walls, interact with cholesterol and other material, and contribute to the inflammatory processes that shape plaque development.

Research suggests that some CHIP mutations, especially those involving TET2, can change how immune cells behave. These cells may produce stronger inflammatory responses, potentially accelerating atherosclerosis and contributing to cardiovascular events.

Much of the detailed evidence about how these mutations drive artery disease comes from laboratory and animal studies. Human studies have found associations between CHIP and cardiovascular outcomes, supporting the concern that these mutations matter beyond their connection to blood cancer.

The key point is straightforward: aging can change not only our arteries, but also the blood cells that interact with them.

Scientists are investigating whether those changes help explain some of the cardiovascular risk that conventional measurements do not fully capture.

Does CHIP explain heart attacks in people with normal cholesterol?

It may help explain some of the variation in cardiovascular risk, but the claim that it explains up to 40% of fatal heart attacks or strokes in people with normal cholesterol is not established by the research.

A landmark study published in the New England Journal of Medicine in 2014 found that age-related mutations in blood-forming cells were associated with higher risks of coronary heart disease and ischemic stroke.

Subsequent research has strengthened the link between CHIP and cardiovascular disease. The American Heart Association's 2026 scientific statement reviews evidence connecting clonal hematopoiesis with atherosclerosis and other cardiovascular conditions.

But three distinctions matter:

• Association is not proof of individual causation. People with CHIP may have higher cardiovascular risk, but a CHIP mutation does not establish why a particular person had a heart attack.
• Not all mutations carry the same risk. The gene involved, the size of the mutated cell population and other health factors can affect the significance of a finding.
• Normal cholesterol does not mean zero cardiovascular risk. Nor does a heart attack in someone with normal cholesterol prove that CHIP was responsible.

The research reveals another possible contributor to cardiovascular disease. It has not identified a single molecular explanation for every event that conventional risk factors fail to predict.

The treatment finding that needs careful interpretation

One of the most intriguing studies appeared in JAMA Cardiology in 2022. Researchers examined blood samples from a subset of participants in the CANTOS trial, which tested an anti-inflammatory drug called canakinumab in people who had previously suffered a heart attack and still had elevated inflammation.

The researchers identified CHIP in 338 participants in the genetic substudy. They then explored whether people with particular mutations responded differently to canakinumab.

Among participants with TET2 mutations, treatment was associated with a lower rate of major cardiovascular events than placebo:

Hazard ratio: 0.38 (95% confidence interval: 0.15–0.96).

That corresponds to an estimated 62% relative reduction in cardiovascular events in that subgroup during the study.

But that headline number needs context.

The analysis involved a small genetic subgroup, and the confidence interval was wide. The true treatment effect could be substantially smaller than the point estimate suggests.

More importantly, the statistical test comparing the treatment effect in people with TET2 mutations against the effect in other participants did not establish a significant difference. The researchers described their analysis as exploratory and called for further studies.

In plain English: the result is an interesting clue that people with certain mutations might respond particularly well to targeted anti-inflammatory treatment. It is not proof that the treatment works differently in people with CHIP, and it does not establish a new treatment recommendation.

Does this mean statins don't work?

No.

The CHIP research does not show that statins fail to protect people with these mutations. It also does not justify replacing cholesterol-lowering treatment with anti-inflammatory medication.

Statins lower LDL cholesterol and reduce cardiovascular events. The evidence supporting those benefits comes from extensive clinical research.

CHIP may contribute to residual cardiovascular risk—the risk that remains even after conventional risk factors have been addressed. Researchers are investigating whether targeting inflammation could provide additional protection for certain patients.

That is a different claim from saying statins have no benefit.

Do not stop or reduce a prescribed statin because of a CHIP result or an article about inflammation. Any treatment change should be discussed with the clinician managing your cardiovascular risk.

Should people with CHIP take anti-inflammatory drugs?

Not on the basis of this research alone.

The CANTOS trial showed that targeting inflammation can reduce cardiovascular events in selected patients with previous heart attacks and elevated inflammation. However, canakinumab also increased the risk of fatal infection, and it is not a routine treatment for CHIP.

Other anti-inflammatory approaches, including low-dose colchicine, have shown cardiovascular benefits in certain patient groups. But those results do not establish that colchicine—or any other anti-inflammatory drug—specifically prevents CHIP-related cardiovascular events.

The American Heart Association's 2026 scientific statement concludes that no CHIP-specific therapies have yet demonstrated proven efficacy for cardiovascular treatment or prevention. Potential approaches, including anti-inflammatory treatments, remain subjects for further research.

A Mediterranean-style eating pattern, regular exercise, not smoking and appropriate control of cholesterol and blood pressure remain sensible prevention strategies. They should not be described as proven ways to eliminate CHIP or reverse its genetic mutations.

Should you worry about leukemia?

This is an understandable concern, but a CHIP finding is not a leukemia diagnosis.

For people with CHIP, the commonly cited average risk of progression to a blood cancer is approximately 0.5% to 1% per year. That is a population-level estimate, not a personal prediction. Risk can be higher or lower depending on the specific mutation, the size of the mutated cell population, the number of mutations and blood-count findings.

Put simply, most people with CHIP do not develop a blood cancer. Nevertheless, the finding should be interpreted in context rather than ignored.

CHIP can also matter because of its association with cardiovascular disease—even when blood counts are normal.

The right response is informed follow-up, not panic.

What if CHIP appears on a genetic test?

CHIP is sometimes discovered incidentally when blood DNA is sequenced for another reason. It is not yet a routine screening test recommended for every older adult.

If a report identifies CHIP, ask the clinician who ordered the test to explain what the finding means in your case. Depending on the mutation, clone size, blood counts and medical history, it may be appropriate to seek a hematology consultation and review cardiovascular risk with your usual clinician or a cardiologist.

Useful questions include:

• Which gene is affected, and how large is the mutated cell population?
• Are my blood counts normal, and do they need monitoring?
• Does this finding warrant a hematology referral?
• Should it change how my existing cardiovascular risk factors are assessed or managed?
• Is there any evidence supporting a specific intervention for my situation?

A CHIP result alone does not mean you need a new medication, a battery of tests or an urgent cancer evaluation. The appropriate follow-up depends on the details.

The bigger discovery: Aging changes the immune system

CHIP is part of a broader field of research into inflammaging—the chronic, low-grade inflammation often associated with aging.

The term does not describe a single disease, and inflammation has many possible causes. Researchers are studying how age-related immune changes, cellular damage and other biological processes interact with cardiovascular health.

CHIP offers a way to investigate one of those processes at the genetic level. If certain mutated cell populations contribute to inflammation, future treatments might be able to reduce their harmful effects or limit their expansion.

That possibility is exciting. But identifying a biological mechanism is only one step toward proving that a treatment improves health and prolongs life.

The next challenge is to determine who is most at risk, whether testing improves medical decisions and which interventions offer more benefit than harm.